Explore more
News
Eli Lilly, Novo Nordisk and Zepbound
Digest more
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...
The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the ...
Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...
Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...
The new research and development site will combine research, process development and clinical trial manufacturing ...
Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback